Maintenance treatment with capecitabine plus cetuximab after first-line standard fluorouracil-based chemotherapy plus cetuximab for patients with RAS wild-type advanced colorectal cancer.

806Background: The optimum duration of first-line treatment with chemotherapy in combination with cetuximab (CET) in patients with RAS wild-type (wt) advanced colorectal cancer (ACRC) is unknown. The current study was designed to evaluate the efficacy and safety of maintenance treatment (MT) with capecitabine (CAP) plus CET in ACRC. Methods: The trial was conducted at Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, China. We included patients with previously untreated RAS wt ACRC, with stable disease or better after induction treatment with 4-6 months of standard fluorouracil-based chemotherapy plus CET, WHO performance status of 0 or 1. The selected patients were assigned to MT-CAP (1250mg/m2 orally twice daily on day 1-14 every 3 weeks), and CET (400 mg/m2 on day 1 of the first week, then 250 mg/m2 on day 1 every week). We assessed disease status every 6 weeks. The primary endpoint of the study was disease progression or unacceptable toxicity, defined as progressi...